Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trial
Summary - The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between the ages of 3 and 18 years. We carried out comprehensive molecular a...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[14 May 2018]
|
| In: |
Cancer cell
Year: 2018, Jahrgang: 33, Heft: 5, Pages: 829-842.e1-35 |
| ISSN: | 1878-3686 |
| DOI: | 10.1016/j.ccell.2018.04.004 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.ccell.2018.04.004 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1535610818301752 
|
| Verfasserangaben: | Alan Mackay, Anna Burford, Valeria Molinari, David T. W. Jones, Elisa Izquierdo, Jurriaan Brouwer-Visser, Felice Giangaspero, Christine Haberler, Torsten Pietsch, Thomas S. Jacques, Dominique Figarella-Branger, Daniel Rodriguez, Paul S. Morgan, Pichai Raman, Angela J. Waanders, Adam C. Resnick, Maura Massimino, Maria Luisa Garrè, Helen Smith, David Capper, Stefan M. Pfister, Thomas Würdinger, Rachel Tam, Josep Garcia, Meghna Das Thakur, Gilles Vassal, Jacques Grill, Tim Jaspan, Pascale Varlet, and Chris Jones |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1676279822 | ||
| 003 | DE-627 | ||
| 005 | 20220816222035.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190909s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ccell.2018.04.004 |2 doi | |
| 035 | |a (DE-627)1676279822 | ||
| 035 | |a (DE-599)KXP1676279822 | ||
| 035 | |a (OCoLC)1341242846 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mackay, Alan |e VerfasserIn |0 (DE-588)1163486515 |0 (DE-627)102783468X |0 (DE-576)508026849 |4 aut | |
| 245 | 1 | 0 | |a Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trial |c Alan Mackay, Anna Burford, Valeria Molinari, David T. W. Jones, Elisa Izquierdo, Jurriaan Brouwer-Visser, Felice Giangaspero, Christine Haberler, Torsten Pietsch, Thomas S. Jacques, Dominique Figarella-Branger, Daniel Rodriguez, Paul S. Morgan, Pichai Raman, Angela J. Waanders, Adam C. Resnick, Maura Massimino, Maria Luisa Garrè, Helen Smith, David Capper, Stefan M. Pfister, Thomas Würdinger, Rachel Tam, Josep Garcia, Meghna Das Thakur, Gilles Vassal, Jacques Grill, Tim Jaspan, Pascale Varlet, and Chris Jones |
| 264 | 1 | |c [14 May 2018] | |
| 300 | |b Illustrationen | ||
| 300 | |a 19 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.09.2019 | ||
| 520 | |a Summary - The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between the ages of 3 and 18 years. We carried out comprehensive molecular analysis integrated with pathology, radiology, and immune profiling. In post-hoc subgroup analysis, hypermutator tumors (mismatch repair deficiency and somatic POLE/POLD1 mutations) and those biologically resembling pleomorphic xanthoastrocytoma ([PXA]-like, driven by BRAF_V600E or NF1 mutation) had significantly more CD8+ tumor-infiltrating lymphocytes, and longer survival with the addition of BEV. Histone H3 subgroups (hemispheric G34R/V and midline K27M) had a worse outcome and were immune cold. Future clinical trials will need to take into account the diversity represented by the term “HGG” in the pediatric population. | ||
| 650 | 4 | |a CD8 | |
| 650 | 4 | |a hypermutator | |
| 650 | 4 | |a immune | |
| 650 | 4 | |a MAPK | |
| 650 | 4 | |a pediatric high-grade glioma | |
| 700 | 1 | |a Jones, David T. W. |e VerfasserIn |0 (DE-588)1058669672 |0 (DE-627)79739334X |0 (DE-576)414823583 |4 aut | |
| 700 | 1 | |a Capper, David |d 1979- |e VerfasserIn |0 (DE-588)133950751 |0 (DE-627)558829902 |0 (DE-576)300212402 |4 aut | |
| 700 | 1 | |a Pfister, Stefan |d 1974- |e VerfasserIn |0 (DE-588)123850215 |0 (DE-627)706450930 |0 (DE-576)293908400 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer cell |d Cambridge, Mass. : Cell Press, 2002 |g 33(2018), 5, Seite 829-842.e1-35 |h Online-Ressource |w (DE-627)343970082 |w (DE-600)2074034-7 |w (DE-576)097935972 |x 1878-3686 |7 nnas |a Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trial |
| 773 | 1 | 8 | |g volume:33 |g year:2018 |g number:5 |g pages:829-842.e1-35 |g extent:19 |a Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ccell.2018.04.004 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1535610818301752 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190909 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 123850215 |a Pfister, Stefan |m 123850215:Pfister, Stefan |d 910000 |d 910500 |e 910000PP123850215 |e 910500PP123850215 |k 0/910000/ |k 1/910000/910500/ |p 21 | ||
| 998 | |g 133950751 |a Capper, David |m 133950751:Capper, David |p 20 | ||
| 998 | |g 1058669672 |a Jones, David T. W. |m 1058669672:Jones, David T. W. |d 50000 |e 50000PJ1058669672 |k 0/50000/ |p 4 | ||
| 999 | |a KXP-PPN1676279822 |e 3513841906 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Alan","display":"Mackay, Alan","role":"aut","family":"Mackay"},{"given":"David T. W.","family":"Jones","role":"aut","display":"Jones, David T. W."},{"given":"David","family":"Capper","role":"aut","display":"Capper, David"},{"given":"Stefan","family":"Pfister","role":"aut","display":"Pfister, Stefan"}],"note":["Gesehen am 09.09.2019"],"language":["eng"],"name":{"displayForm":["Alan Mackay, Anna Burford, Valeria Molinari, David T. W. Jones, Elisa Izquierdo, Jurriaan Brouwer-Visser, Felice Giangaspero, Christine Haberler, Torsten Pietsch, Thomas S. Jacques, Dominique Figarella-Branger, Daniel Rodriguez, Paul S. Morgan, Pichai Raman, Angela J. Waanders, Adam C. Resnick, Maura Massimino, Maria Luisa Garrè, Helen Smith, David Capper, Stefan M. Pfister, Thomas Würdinger, Rachel Tam, Josep Garcia, Meghna Das Thakur, Gilles Vassal, Jacques Grill, Tim Jaspan, Pascale Varlet, and Chris Jones"]},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"[14 May 2018]"}],"recId":"1676279822","id":{"doi":["10.1016/j.ccell.2018.04.004"],"eki":["1676279822"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"19 S.","noteIll":"Illustrationen"}],"title":[{"title":"Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trial","title_sort":"Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trial"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Cancer cell","title_sort":"Cancer cell"}],"part":{"extent":"19","year":"2018","pages":"829-842.e1-35","issue":"5","text":"33(2018), 5, Seite 829-842.e1-35","volume":"33"},"note":["Gesehen am 28.02.11"],"pubHistory":["1.2002 -"],"language":["eng"],"disp":"Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trialCancer cell","origin":[{"publisherPlace":"Cambridge, Mass. ; New York, NY","dateIssuedKey":"2002","dateIssuedDisp":"2002-","publisher":"Cell Press ; Elsevier"}],"recId":"343970082","id":{"zdb":["2074034-7"],"eki":["343970082"],"issn":["1878-3686"]},"type":{"media":"Online-Ressource","bibl":"periodical"}}]} | ||
| SRT | |a MACKAYALANMOLECULARP1420 | ||